Trial Profile
A Retrospective study to evaluate the therapeutic efficacy of SM-88 using the SUV and RECIST in Cancer patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2018
Price :
$35
*
At a glance
- Drugs Racemetyrosine (Primary) ; Racemetyrosine (Primary)
- Indications Breast cancer; Cancer; Ewing's sarcoma; Renal cancer; Thyroid cancer
- Focus Therapeutic Use
- 20 Jun 2018 Patients' gender and age group has been assumed.
- 20 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology